A Phase 1 interventional study of GC3107 in Tuberculosis, sponsored by Green Cross Corporation. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-18.
Sponsored by Green Cross Corporation · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Tuberculosis with a site in Korea, Republic of — 4 open to participants now, 4 under way, 1 of them phase 3. Tuberculosis · Korea, Republic of.
Among the 46 studies in Tuberculosis with a site in Korea, Republic of, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2017, is one of 3 in phase 1, and was the 32nd registered.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
Browse Tuberculosis studies →4 of the 46 studies in Tuberculosis with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
Viatris Inc. · Sites in Korea, Republic of
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–85
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.
This study: 19 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Median enrollment 104 across the 24 interventional studies, 222 across the 22 observational. Of the 28 that completed or were terminated, 6 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Green Cross Corporation, one of the names counted as GC Biopharma Corp.. Under that name alone:
Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
GC Biopharma Corp. has 2 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 46 studies in Tuberculosis with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.
Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally. Tuberculin Skin Test(TST) will be conducted after 84+7 days after IP injection and TST result will be read in 48\~72 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BCG Vaccine, 0.1mL
Biological: GC3107
BCG Vaccine, 0.1mL
Adverse Event
Solicited/Unsolicited Adverse Event
Time frame: for 7 days from Day0/during study period
Whether the maximum Induration diameter greater than 5mm after TST.
Induration diameter measured in the direction perpendicular to the arm.
Time frame: Day0+84days
Whether the maximum Erythema/Redness diameter greater than 5mm after TST.
Erythema/Redness diameter measured in the direction perpendicular to the arm.
Time frame: Day0+84days
Maximum diameter of Induration after TST.
Induration diameter measured in the direction perpendicular to the arm.
Time frame: Day0+84days
Maximum diameter of Erythema/Redness after TST.
Erythema/Redness diameter measured in the direction perpendicular to the arm.
Time frame: Day0+84days
Maximum diameter variation of Induration after TST.
Induration diameter measured in the direction perpendicular to the arm.
Time frame: Day0+84days
Maximum diameter variation of Erythema/Redness after TST.
Erythema/Redness diameter measured in the direction perpendicular to the arm.
Time frame: Day0+84days
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2017 (actual). Primary completion is estimated for Mar 2018, 3 months after the start.
Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.